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Abstract: 
Introduction: Lymphomas are the third most often diagnosed malignant neoplasms among 
children and adolescents. They constitute about 10-15% of childhood malignancies. We 
aimed to quantify incidence of Lymphomas (HD and NHD) in the Gezira State and their 
difference with gender and age. 
Methods: The data was abstracted and classified accordingly to the third revision of the 
International Classification of Childhood Cancer. Age-standardised rates (ASR) for three 
5-year age groups (0–4 years, 5–9 years and 10–14 years) calculated for males and females. 
Results: The total number of children diagnosed with lymphoma was 140 patients. 
NHL forms 75/140(53%) and HD 65/140(46%). Incidence of NHL was 6.68/million. 
Males with NHL was 48/75 (64%) with an ASR of 5.71/million and females 27/75(36%) 
with ASR of 4.04/million and a ratio of 1.7:1. The most common age group of presentation 
of NHL in males was 5-9 years of age, while in females was from 10-14 years of age. 
Incidence of HD was 4.22/million. Males constituted about 40/65 (62%) with an ASR of 
4.72/million, while females were 25/65(38%) with and ASR of 3.72 and males to females 
ratio of 1.6:1. The common age of presentation of HD in both males and females was 5-9 
years of age. 
In conclusion: The results presented in this study were similar with international results 
and comparable with them. implemented analytical studies to clarify the different 
types of haematological malignancies will help to choose the right treatment and better 
cure.  
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Introduction: 
Lymphomas are the third most frequently diagnosed malignant neoplasms among children 
and adolescents (1). They constitute 10-15% of childhood malignancies. Non-Hodgkin 
lymphoma accounts for approximately 60% of all lymphomas in children and adolescents. 
They constitute a heterogeneous group of malignant tumors of lymphoid tissues derived 
from mature B or T cells (2). The histological pattern of NHL in children differs from that 
in adults. While indolent lymphoma is common in adults, high grade lymphoma is the 
predominant lymphoma in children (3).  
 Lymphoma was the most prevalent childhood malignancy in the National Cancer Institute, 
University of Gezira (NCI-U of G)  where it acounted for (42.8%) (4). The incidence of 
Hodgkin’s lymphoma in Yemen  and Lebanon is more than 5.5/100000, while it is less than 
1/100000 in China and Japan (5) 
The incidence of Non - Hodgkin Lymphoma  has increased in the western world over recent 
decades, rising by 3 – 5% per annum (5). NHL has become the fifth most common cancer 
in the USA, occurring at a frequency of approximately 17.4 per 100000. It is slightly more 
common in males than in females, and is more common in white people than in black people 
(5). 
 
Material and Methods: 
Procedure:  
In this epidemiological, population-based registry study, multiple data sources were used 
including hospitals records (Public and Private), pathology laboratories, and death 
certificates that remain the major sources for case finding, beside access to oncology 
departments at Wad Madani and Radio Isotope Center Khartoum, imaging techniques and 
haematology laboratories.   
Cancer patients’ data were abstracted from medical records, based on clinical and/or 
histopathology diagnosis, by Gezira Cancer Registry trained cancer registrars. The data 
abstracted included personal identification (name, sex, and age), demographic information 
(including: address, telephone number, ethnic groups, place of birth), and tumor details 
(date of diagnosis, primary site, histology, behavior, grade, stage, basis of diagnosis). The 
primary site (topography) and histology (morphology) of the malignancies were identified 
and coded according to the International Classification of Diseases for Oncology 3rd 
Edition (ICD-O-3), published by the World Health Organization (WHO), 2000 (6). From 
the ICD-O3 codes each case was classified according to the third revision of the 
International Classification of Childhood Cancer (ICCC-3) (7)  
The computer software programs CanReg 5.42 (the last update-released programme) was 
used to enter the data. The registry confidentiality is based and depended on restricted 
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First, we calculated age-specific incidence rates (ASR) for three 5-year age groups (0–4 
years, 5–9 years and10–14 years) 
We defined the number of cases and the number of person-years (males and Females) for 
the applicable times, and the result was expressed per million persons per years. We defined 
person-years as the sum of the population counts in Gezira State in each year from the first, 
of January 2005 to 31 of December 2014, categorised by gender.  
The age-standardised rate (ASR) was calculated, using the age-specific rates (R1, R2, R3) 
and the world standard population (Table 1), for the three age groups 0–4, 5–9, and 10–14: 
ASR = [(R1 × 12000) (R2 × 10000) (R3 × 9000)]/31000. 
We calculated the sex ratios by dividing the incidence in male individuals with that in 
female individuals. Statistical analysis was done using SPSS version 23 IBM. 
 
Results: 
In the current study, the total numbers of children diagnosed with lymphoma were 140 
during the study period. The males were 88/140(62%) and the females were 52/140(38%) 
with a male to female ratio of 1.6:1. NHL  accounted for 75/140 (53%) and HD for 65/140 
(46%). 
The incidence of NHL was 6.68/million. Males with NHL were 48(64%) with an ASR of 
5.71/million and females 27(36%) with ASR of 4.04/million and a ratio of 1.7:1. The age 
specific rate for NHL was different according to the age group and gender (Table 2). In 
males with NHL from 0-4 years was 4.75/million, from 5-9 was 6.95/million and from 10-
14 years was 5.62/million. While in females, the age ASR according to the age distribution 
from 0-4 years was 4.21/million, from 5-9 years was 3.61/million and from 10-14 years 
was 4.28/million. The common age group presentation of NHL in the males was 5-9 years 
of age while in the females was 10-14 years of age (Table 2). 
The incidence of HD is 4.22/ millions. Males  accounted for 40/65 (62%) with an ASR of 
4.72/ million, while females were 25/65 (38%) with ASR of 3.72/million and males to 
females ratio of 1.6:1 (Table 2). The age specific rate was (3.39, 5.85 and 5.24) per million 
for males at age groups (0-4, 5-9 and 10-14 years respectively); while in females were (3.3, 
4.47 and 3.80) per million for age groups (0-4, 5-9 and 10-14 years respectively) (Table 2). 
The common age of presentation of HD in both males and females was from 5-9 years of 
age (Table 2). 
Figure: 1A illustrates the percentage distribution of the most frequent lymphoma by 
individual year of age. There was considerable variation between males and females in the 
age at diagnosis. in the case of Hodgkin Lymphoma which was more frequent in males at 
Age 5, 10 and 14 years accounting for 16%, 10% and 10% respectively. However, there is 
one peak in females at age of diagnosis 14 years accounting for 14% of the females cases.  
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Males diagnosed with Non-Hodgkin lymphoma were over two year old, and had three peaks 
of frequent at age of diagnosis 4, 7 and 14 years accounting for   8%, 7% and 8% 
respectively. Females had two peaks at age of diagnosis 3 and 5 years (Figure: 1B). 
Age standardised rate for Non-Hodgkin lymphoma had two peaks in males 2007-2008 and 
2011-2012, while in females had one peak in 2007-2008 (figure: 2), as well as Hodgkin 
lymphoma (Figure: 3). 
Figure: 4 and 5 showed a comparison of Sudanese NHL and HL age standardized rate per 
million according to age and gender from 2005-2014 with African, North America, 
European and Asian cancer registries.      
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Table (2): Hodgkin’s lymphoma and Non- Hodgkin lymphoma age specific rate and 
ASR per million by age and gender 
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Note: - N: Number, M: Male, F: Female and ASR: Age Standardized rate, ALL: Males and 
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Figure 1: Percent distribution of study subject by age and gender according to age at 
diagnosis 2005-2014: 
 A: Hodgkin lymphoma 
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 Figure 2: Non-Hodgkin lymphoma average of two years age standardization 
incidence rate per million by age and gender, 2005-2014 
Figure 3: Hodgkin lymphoma average of two years age standardization incidence 
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Figure 4: Comparison of Non-Hodgkin lymphoma age standardization incidence 
rate per million by age and gender,   2005-2014: 
A: African registries 
B: North America registries 
C: European registries 
D: Asian registries 
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Figure 5: Comparison of Hodgkin lymphoma age standardization incidence 
rate per million by age and gender,   2005-2014  
A: African registries 
B: North America registries 
C: European registries 
D: Asian registries 
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The National Cancer Institute, University of Gezira is the only center of oncology in Gezira 
to which sent the most children diagnosed with lymphoma in Gezira State. In addition to 
active data collected from Gezira and other resources indicated that our result is 
representative of the Gezira State populations. Interestingly, this is first study on lymphoma 
in Sudan, which reported the incidence rates per millions and compared the results with the 
most recent published data from different cancer registries in Africa, North America, 
Europe and Asia.  
There is variation in age-specific incidence in African Hodgkin lymphoma children. Some 
countries reporting the higher rate at age 5–9 than at 10–14 (10). Our data showing increased 
in incidence rates in age 5–9 in both males and females (5.85 and 4.07 per millions 
respectively) than at age 10–14. Hodgkin lymphoma is more common among males than 
in females (11). In present study sex ratio among males and females  were found to be higher 
than in the USA (1.3 M/F) but nearer to that in Europe (1.6 and 1.7 M/F respectively) (11).  
In  East Africa, the ASR is greater two times in Ethiopian  than in Sudan, however, 
incidence rates  were  similar to the findings reported in Malawi, Uganda, Mauritius and 
Zimbabwe (5.6, 4.5, 5.6 and 3.2 per millions respectively) (10).The  incidences rates in West 
Africa are  more less than the   Gezira rates. Whereas, higher incidence rates was publicized 
in Mali (10).  Stiller and Parkin   reported that it was not possible to estimate the acquired 
incidence rates of childhood Hodgkin disease in Africa, however,  the incidence in many 
African countries may indeed similar to that in developed ones (12).ASR results for HL in 
Sudanese was lower than European countries Norway, Ireland, Germany, France and 
Turkey. It was higher than Asian countries Saudi Arabia, Kuwait , Jordan  and Japan (11). 
These differences between our age incidence compared to the foreign countries may be 
explained by the interplay of both environmental and racial factors (13). 
Non –Hodgkin lymphoma in childhood is always near high grades.  Lymphoma, other  than 
BL usually have total ASR of 5- 9 per millions, though incidence rates may be a little higher 
than in North Africa (Algeria and Egypt) (10). However, the North Africa may have genes 
and environmental factors that may be involved in occurring incidences. 
In East Africa there is a variation in the incidence rates of NHL, while it was higher in 
Uganda and lower in Kenya  (10). In USA the rates in dark skin, populations have lower 
rates than in whites. This may probably explained by environmental changes and exposures. 
In Asian countries, such as Kingdom of Saudia Arabia (KSA) and Japan were showed 
similar outcomes of ASR when compared to Gezira cancer consequences, Sudan. 
Moreover, some other countries like Turkey and Jordan showed higher incidence in males 
than in females, while Kuwait showed the lower differences between males and females. 
Additionally, the Kuwaiti females  showed the highest incidence rates of NHL among  those 
in Arabs countries (11).  The incidence of NHL among females in European countries was 
found to be similar to that obtained in Gezira incidence data. However, the incidences in  
males ASR are higher (11). A comparison of  NHL in Gezira, Sudan ASR result was higher  
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than in North American registries , we found that our  ASR result was higher than NPCR 
(Native American population) and lower than USA dark colors people and Canadian (11). 
In conclusion, our data presented in this study was similar with international result and 
comparable with them. Implemented  knew tools like molecular techniques will improve 
the detection of different types of tumors  and help to choose the right treatment and 
prophylaxis for better cure of haematolgical malignancies among Sudanese children. 
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